IPO Proposal of Nivix Pharmaceuticals Limited Added to SEBON's Pipeline

The IPO proposal of Nivix Pharmaceuticals Limited has been added to SEBON's pipeline.

Nivix Pharmaceuticals Limited has submitted a proposal to issue 1,375,000 shares at a par value of Rs. 100 per share. This IPO issue will generate Rs. 13.75 crore for the company. Nepal SBI Merchant Banking has been appointed the issue manager for this issue. The proposal was submitted on Mangsir 30, 2082, at SEBON.

It is only after the approval from the regulatory board SEBON, the company can float the shares to the general public.

Infomerics Credit Rating Nepal Limited has given the company an IRN B+ (Is) rating, indicating that it carries a high risk of default in meeting its financial obligations on time.

Nivix Pharmaceuticals Limited (NIVIX), originally founded as Pokhara Pharmaceuticals in July 2017, was converted from a private to a public limited company in December 2024. Licensed by the Department of Drug Administration, the company produces and distributes allopathic medicines, operating from its corporate office in Pokhara and its manufacturing plant in Tanahun. By May 2025, NIVIX held manufacturing licenses for 84 products, marketing licenses for 45 products, and marketed 42 products in Nepal. Its largest shareholder is Mr. Indra Baniya, with about 20% ownership.